Exemplary studies conducted in SCA3, HD and, to a lesser extent, SCA2 models convincingly demonstrated that modifying cholesterol biosynthesis can ameliorate disease symptoms in vivo by enhancing autophagy and the UPS (Kacher et al., 2019; Nóbrega et al., 2019) (Table 1). Here, ATXN2 is linked to Huntington disease.